COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
The current price of CMPS is $11.87 USD — it has decreased by -1.74% in the past 24 hours. Watch Compass Pathways stock price performance more closely on the chart.
What is Compass Pathways stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Compass Pathways stocks are traded under the ticker CMPS.
Is Compass Pathways stock price growing?▼
CMPS stock has risen by +1.02% compared to the previous week, the month change is a +14.27% rise, over the last year Compass Pathways has showed a +169.93% increase.
What were Compass Pathways earnings last quarter?▼
CMPS earnings for the last quarter are -0.41 USD per share, whereas the estimation was -0.38 USD resulting in a -7.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Compass Pathways revenue for the last year?▼
Compass Pathways revenue for the last year amounts to 0 USD.
What is Compass Pathways net income for the last year?▼
CMPS net income for the last year is -310.24M USD.
How many employees does Compass Pathways have?▼
As of June 15, 2026, the company has 166 employees.
In which sector is Compass Pathways located?▼
Compass Pathways operates in the Health & Wellness sector.
When did Compass Pathways complete a stock split?▼
Compass Pathways has not had any recent stock splits.
Where is Compass Pathways headquartered?▼
Compass Pathways is headquartered in London, United States.